- Home
- PSNL
PSNL
Personalis Inc.
as 07-26-2024 4:00pm EST
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 86.2M | IPO Year: | 2019 |
| Target Price: | $5.00 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $4.52 | Next Earning Date: | 08-07-2024 |
| Revenue: | $74,146,000 | Revenue Growth: | 7.96% |
| Revenue Growth (this year): | 6.85% | Revenue Growth (next year): | 10.15% |
Stock Insider Trading Activity of Personalis Inc. (PSNL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | Jun 17 '24 | Sell | $1.29 | 1,585 | $2,044.65 | 69,081 | SEC Form 4 |
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Jun 17 '24 | Sell | $1.29 | 5,055 | $6,520.95 | 127,751 | SEC Form 4 |
| Tachibana Aaron | PSNL | CFO AND COO | Jun 17 '24 | Sell | $1.29 | 7,176 | $9,257.04 | 176,012 | SEC Form 4 |
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | May 17 '24 | Sell | $1.38 | 940 | $1,297.20 | 132,806 | SEC Form 4 |
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | May 17 '24 | Sell | $1.38 | 1,731 | $2,388.78 | 70,666 | SEC Form 4 |
| Tachibana Aaron | PSNL | CFO AND COO | May 17 '24 | Sell | $1.38 | 1,333 | $1,839.54 | 183,188 | SEC Form 4 |
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | Apr 30 '24 | Sell | $1.37 | 4,523 | $6,196.51 | 72,397 | SEC Form 4 |
| MYERS WOODROW A JR | PSNL | Director | Mar 1 '24 | Buy | $1.67 | 10,000 | $16,700.00 | 26,116 | SEC Form 4 |
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Jan 29 '24 | Sell | $1.37 | 526 | $720.62 | 128,870 | SEC Form 4 |
| Tachibana Aaron | PSNL | CFO AND COO | Jan 29 '24 | Sell | $1.37 | 716 | $980.92 | 184,521 | SEC Form 4 |
| Tachibana Aaron | PSNL | CFO and COO | Dec 15 '23 | Sell | $1.47 | 6,747 | $9,918.09 | 185,237 | SEC Form 4 |
| Moore Stephen Michael | PSNL | General Counsel | Dec 15 '23 | Sell | $1.47 | 1,476 | $2,169.72 | 76,920 | SEC Form 4 |
| Chen Richard | PSNL | Chief Medical Officer and EVP | Dec 15 '23 | Sell | $1.47 | 4,708 | $6,920.76 | 129,396 | SEC Form 4 |
Latest Personalis Inc. News
PSNL Breaking Stock News: Dive into PSNL Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Personalis to Announce Second Quarter 2024 Financial Results
Simply Wall St.
7 days ago
Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years
Zacks
11 days ago
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
MT Newswires
15 days ago
Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests
GlobeNewswire
15 days ago
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Business Wire
a month ago
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
Business Wire
a month ago
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
Business Wire
2 months ago
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Compare PSNL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSNL Personalis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.